Bolt Biotherapeutics Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company's pipeline reflects biology and cancer drug development. Its lead program includes BDC-4182. Bolt Biotherapeutics Inc., formerly known as BOLT THERAPT, is based in REDWOOD CITY, Calif.
| Revenue (Most Recent Fiscal Year) | $7.70M |
| Net Income (Most Recent Fiscal Year) | $-33.38M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.64 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.61 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -611.47% |
| Net Margin (Trailing 12 Months) | -611.47% |
| Return on Equity (Trailing 12 Months) | -126.23% |
| Return on Assets (Trailing 12 Months) | -54.70% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.61 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.61 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.47 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $13.81 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-4.57 |
| Earnings per Share (Most Recent Fiscal Year) | $-17.85 |
| Diluted Earnings per Share (Trailing 12 Months) | $-16.44 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 1.93M |
| Free Float | 1.75M |
| Market Capitalization | $7.71M |
| Average Volume (Last 20 Days) | 0.02M |
| Beta (Past 60 Months) | 1.00 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.70% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |